Xcell Therapeutics to Present CellCor™ CD MSC, a Serum-Free Chemically defined Media, at BIO KOREA 2022! 

Xcell Therapeutics (CEO Lee Yi Il) will participate in BIO KOREA 2022, which will be held at COEX in Seoul from May 11th (Wed) to 13th (Fri).

Founded in 2015, Xcell Therapeutics has secured serum-free chemotactic culture medium technology and established a mass culture system in less than three years. This has enabled the company to eliminate animal-derived ingredients and secure raw materials for cellular therapeutics consisting of only chemically identifiable components. It is a promising technology that not only solves the disadvantages of conventional serum media, which are free from commercial, ethical, and technical problems, but also solves the problem of slow cell growth in culture.

In addition, Xcell Therapeutics has succeeded in building a cell culture medium production facility that can produce 100,000L of products per year to secure competitiveness in the global medical market. Furthermore, the company is preparing to secure additional production facilities by purchasing a site in the Osong Advanced Medical Complex in Chungcheongbuk-do, with the goal of completing the second plant in 2022.

At the exhibition, Xcell Therapeutics will introduce CellCor™ CD MSCs. CellCor™ CD MSCs are manufactured using serum-free chemotactic culture media technology and are regulatory friendly as they are free of animal and human-derived ingredients. It is also produced in GMP-compliant facilities to ensure high quality and consistency. This allows for high reproducibility.

CellCor™ CD MSC is a chemotaxis medium that follows the trend of the advanced biotechnology industry to find a way to be free from regulations. It is applicable to stem cells and is expected to gain traction in the biopharmaceutical market, where there is a strong demand for culture media to replace conventional FBS and serum.

"Since the commercialization of our products in 2020, the high demand has enabled us to more than double our growth rate from the previous year, and we are very excited about our future prospects," said a representative from Xcell Therapeutics.

"We are also planning to launch two more exosome-related products, CellCor™ EXO and the immunization medium CellCor™ NK, to increase our market presence once again."

Meanwhile, BIO KOREA 2022, now in its 17th year, is organized by the Korea Health Industry Promotion Agency and Chungcheongbuk-do. BIO KOREA has established itself as Korea's leading international biohealth convention, attracting world-class scholars and business experts every year. BIO KOREA 2022 will feature a variety of programs including conferences, business forums, exhibitions, and an investor fair, and will be attended by domestic and international companies from the bio, pharmaceutical, medical device, cosmetics, and food industries, as well as interested companies and institutions from consulting, academia, and related organizations.

Source : AVING (https://kr.aving.net)